About Novomix
Novomix is a Healthcare company based in Mahape (India). It develops and manufactures pharmaceutical excipients for industry applications. It operates on a B2B model. The company has 107 employees. Its Indian entity Novo Excipients Private Limited reported revenue of ₹104 Cr. Its focus areas include Pharmaceuticals, Manufacturing and Excipients Production. Its competitors include Accent Microcell and Amster Microcell; 1 of its 2 listed competitors has raised funding.
Company details
Novomix operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and excipients production. Develops and manufactures pharmaceutical excipients for industry applications. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters Mahape, India
- Employees 107
- SectorsHealthcare
- Website novomix.in
- Legal Name Novo Excipients Private Limited
- Date of Incorporation 01 Oct, 2003
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹104 Cr
FY 2025 · -1% YoY
- Net Profit₹18.67 Cr
FY 2025 · 18% margin
- EBITDA₹25.92 Cr
FY 2025 · 25% margin
- Employee Count107
Associated legal entities of Novomix
Novomix operates through Novo Excipients Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Novo Excipients Private Limited CIN U24230MH2003PTC142463 | Active | 01 Oct 2003 | Mumbai, Maharashtra | ₹104 Cr | 107 | 2 | View details |
Board of directors of Novo Excipients Private Limited (Novomix)
Novo Excipients Private Limited is the primary company behind Novomix. The board of Novo Excipients Private Limited currently have 2 directors; the longest-serving is Gautam Chandrakumar Shah, appointed in 2003. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gautam Chandrakumar Shah DIN 00271794 | Managing Director | 01 Oct 2003 | 23 yrs 1 mo | Novo Excipients Private Limited |
| Bimal Shantilal Doshi DIN 00978718 | Director | 14 Jun 2011 | 15 yrs 4 mo | Novo Excipients Private Limited |
Financials of Novomix
Figures of Novo Excipients Private Limited, the primary company behind Novomix, for FY 2025. Revenue was ₹104 Cr (-1% year on year). Net profit was ₹18.67 Cr (18% margin). EBITDA was ₹25.92 Cr (25% margin). Revenue has grown at a compounded annual rate of +27% over three years and +26% over five years.
- ₹104 CrRevenue · FY 2025 · -1% YoY
- ₹18.67 CrNet profit · 18% margin
- ₹25.92 CrEBITDA · 25% margin
- ₹2 LakhPaid-up capital
- 107Employees (provident fund records)
- +27%Revenue CAGR, 3 years
- +26%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Novo Excipients Private Limited are on its company page.
Detailed financial statements for Novomix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Novomix
Novomix has 2 listed competitors in our database, 1 of them funded. They include Accent Microcell and Amster Microcell.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| accentmicrocell.com | 2001 | Ahmedabad, India | $1.5M | 42 | Microcrystalline cellulose and excipients are manufactured by Accent Microcell. | |
| amstermicrocell.com | 2018 | India | 17 | Produces excipients like microcrystalline cellulose for pharmaceutical and nutraceutical industries. |
Detailed competitors of Novomix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Novomix
Novomix is headquartered in Mahape, India. It is registered at Mahape, Maharashtra, India.
Novomix has 107 employees.
The primary company behind Novomix, Novo Excipients Private Limited, reported revenue of ₹104 Cr for FY 2025, down 1% year on year.
Novomix operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and excipients production. Develops and manufactures pharmaceutical excipients for industry applications. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Novomix's top competitors include Accent Microcell and Amster Microcell.
Novomix operates through Novo Excipients Private Limited.
The legal entities of Novomix currently have 2 directors, including Gautam Chandrakumar Shah, Bimal Shantilal Doshi.